Shopping Cart
- Remove All
- Your shopping cart is currently empty
Keap1-Nrf2-IN-4, a powerful neddylation inhibitor, demonstrates significant anti-proliferation activity against MGC-803 cells (IC50 = 2.55 μM), effectively impeding their migration and inducing apoptosis. Additionally, it effectively inhibits tumor growth while exhibiting minimal toxicity [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 10-14 weeks | |
50 mg | $1,980 | 10-14 weeks | |
100 mg | $2,500 | 10-14 weeks |
Description | Keap1-Nrf2-IN-4, a powerful neddylation inhibitor, demonstrates significant anti-proliferation activity against MGC-803 cells (IC50 = 2.55 μM), effectively impeding their migration and inducing apoptosis. Additionally, it effectively inhibits tumor growth while exhibiting minimal toxicity [1]. |
In vitro | Keap1-Nrf2-IN-4 (compound 4g) shows significant anti-proliferative effects with IC50 values of 2.55, 3.88, 3.74, and 2.89 μM in MGC-803, MCF-7, A549, and HepG-2 cell lines, respectively, after 72 hours. It inhibits the neddylation of cullin1, cullin3, and cullin5, obstructs the migratory ability of MGC-803 cells without causing cell cycle arrest, and induces apoptosis in MGC-803 and HGC-27 cells in a concentration- and time-dependent manner when applied for 24 and 48 hours, indicating its potential as a cancer therapeutic. |
In vivo | Keap1-Nrf2-IN-4, administered orally at dosages of 50 and 100 mg/kg daily for a duration of 21 days, demonstrated effective antitumor activity in a xenograft model utilizing 5-6 weeks old, 18-20 g NOD SCID mice, without manifesting any evident adverse effects [1]. |
Molecular Weight | 390.56 |
Formula | C26H34N2O |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.